(l-r) Paul Mizue, President of the Hawaii Prostate Cancer Coalition, Mark Scholz, MD, and Phil Olsen, HPCC Founder

Dr. Mark Scholz, Medical Director of Prostate Oncology Specialists, Marina del Rey, CA was guest speaker at the November 11, 2015 Kuakini US Too support group meeting. He discussed the features of the two new drugs for advanced prostate cancer, abiraterone (Zytiga) and enzalutamide (Xtandi), their appropriate applications for patients, side effects, use in mono-therapy or in combination, and effectiveness in halting prostate cancer progression.